Current evidences on vascular endothelial growth factor polymorphisms and breast cancer susceptibility |
| |
| Authors: | Li-Xin?Qiu author-information" > author-information__contact u-icon-before" > mailto:mdqiulixin@hotmail.com" title=" mdqiulixin@hotmail.com" itemprop=" email" data-track=" click" data-track-action=" Email author" data-track-label=" " >Email author,Ke?Wang,Sheng?Yang,Chen?Mao,Lei?Zhao,Lei?Yao,Jian?Zhang,Qun-Ling?Zhang,Si?Sun,Kai?Xue |
| |
| Affiliation: | (1) Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China;(2) Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China;(3) Institute of Respiratory Diseases, First Affiliated Hospital, Guangxi Medical University, Nanning, China;(4) Department of Medical Oncology, Union Hospital, Fu Jian Medical University, Fuzhou, China;(5) Department of Epidemiology, School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, China;(6) Department of Epidemiology, School of Public Health, Wuhan University, Wuhan, China;(7) State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, China |
| |
| Abstract: | Several polymorphisms of vascular endothelial growth factor (VEGF) such as 936 C/T, −2578 C/A, −406 C/T, and −1154 G/A polymorphism have been identified. Published data on the association between VEGF polymorphisms and breast cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Crude OR with 95% CI was used to assess the strength of association between them. For VEGF 936C/T polymorphism, a total of 10 studies including 7,685 cases and 7,915 controls were involved in this meta-analysis. Overall, no significant associations were found between VEGF 936C/T polymorphism and breast cancer risk when all studies pooled into the meta-analysis (TC vs. CC: OR = 0.904, 95% CI = 0.797–1.024; TT vs. CC: OR = 0.974, 95% CI = 0.786–1.205; dominant model: OR = 0.911, 95% CI = 0.811–1.024; and recessive model: OR = 0.991, 95% CI = 0.801–1.226). In the subgroup analysis by ethnicity, still no significant associations were found for all comparison models. For −2578 C/A, −406 C/T, and −1154 G/A polymorphism, there were too limited data to perform a meta-analysis. In conclusion, this meta-analysis suggests that the VEGF 936C/T polymorphism may be not associated with breast cancer development. However, large sample and representative population-based studies with homogeneous breast cancer patients and well matched controls are warranted to confirm this finding. |
| |
| Keywords: | |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
|
